Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chronic myeloid leukemia]

R Hehlmann1

  • 1III. Medizinische Klinik, Klinikum Mannheim, Universität Heidelberg, Mannheim.

Therapeutische Umschau. Revue Therapeutique
|February 1, 1996
PubMed
Summary
This summary is machine-generated.

Chronic myelogenous leukemia (CML) is a stem cell disease. Current treatments include bone marrow transplant and drugs like interferon alpha and hydroxyurea, with ongoing trials comparing therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Leukemia·2018
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Leukemia·2017
Same author

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

Leukemia·2016
Same author

Prof. Thomas Büchner (22 September 1934-5 August 2016)-A leading European hematologist and AML trialist.

Leukemia·2016
Same journal

[Multimodal Cardiac Imaging: New Developments for Clinical Practice].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Multimodal imaging in cardiac amyloidosis and cardiac sarcoidosis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

State-of-the-Art Cardiac Imaging

Therapeutische Umschau. Revue therapeutique·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology

Context:

  • Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder with a typical progression from a chronic phase to a prognostically unfavorable blast phase.
  • The incidence of CML is approximately 2 per 100,000 individuals annually, with a median age at diagnosis around 47 years.

Purpose:

  • To review current therapeutic options for CML, including allogeneic bone marrow transplantation (BMT) and drug therapies such as interferon alpha (IFN) and hydroxyurea.
  • To discuss the efficacy of these treatments in prolonging the chronic phase and survival, and to highlight the importance of patient risk profiles and treatment intensity.

Summary:

  • Allogeneic bone marrow transplantation (BMT) is the current therapy of choice for CML, offering a cure in 40-80% of cases, particularly for patients under 55.
  • Interferon alpha (IFN) and hydroxyurea are superior to busulfan, improving chronic phase duration and survival, though complete cytogenetic remission rates with IFN are low.

Related Experiment Videos

  • Treatment outcomes depend on factors like drug intensity and patient characteristics, necessitating consideration of risk profiles in survival analyses.

    • Impact:

    • Future CML therapy may involve intensive chemotherapy with or without autografting.
    • Ongoing clinical trials are crucial for evaluating both conventional and novel treatment modalities, including comparisons between allogeneic BMT and optimized drug therapies.